While Praxis moves forward, Neurocrine drops its essential tremor drug
While Neurocrine Biosciences continues to grow the sales of its tardive dyskinesia drug for patients who experience uncommon side effects from mental health drugs, it hit a snag in its development of an essential tremor drug.
In a Phase II study with 30 patients, the candidate, a T-type calcium channel blocker dubbed NBI-827104, did not meet its endpoints, and Neurocrine doesn’t plan to study the drug further for essential tremor, CMO Eiry Roberts said during Neurocrine’s Q2 investor call.
“Topline efficacy results from the study were negative,” she said.
Neurocrine is also looking at the calcium channel blocker in a Phase II epilepsy study, which has completed enrollment. The San Diego-based biotech plans to have topline results for that trial by the end of this year.
Roberts emphasized that the essential tremor results don’t impact the outlook of the epilepsy trial, and added during a Q&A that the two patient populations are very different. While the essential tremor study was in adult patients, the epilepsy trial is in pediatric patients who have a rare form of the disease.
In May, Praxis posted positive Phase II results on its T-type calcium channel blocker in essential tremor. It is currently testing that drug in a larger Phase II study, set to finish in September, according to the government’s clinical trials site.
In 2019, Neurocrine paid Idorsia $5 million upfront for a licensing option on the calcium channel blocker, and the following year exercised that option for $45 million.
The biotech also plans to file for an added indication for its tardive dyskinesia drug valbenazine — marketed as Ingrezza in the US — in Huntington’s disease later this year, after showing in a Phase III trial that the drug improved involuntary movement associated with the disease.